{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"The proportion of efficacy-evaluable patients who achieve complete response (CR) or partial response (PR), per investigator assessment, in accordance with RECIST 1.1 or iRECIST (for solid tumor patients) or Response Assessment in Neuro-Oncology (RANO) criteria (for glioblastoma patients).","groups":[{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG000","title":"Dose Regimen A (DR-A) PTCL Expansion"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 3 and 5 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG001","title":"Dose Regimen C (DR-C) PTCL Expansion"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From Day 1 of treatment until 30 days after the last cycle of treatment (each cycle in DR-A is 28 days, DR-B and DR-C is 21 days), an average of 138 Days","title":"Determine Overall Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}